Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 8829–8836 | Cite as

Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies

  • Renjie Wu
  • Yingjiu Jiang
  • Qingcheng Wu
  • Qiang Li
  • Dan Cheng
  • Ling Xu
  • Cheng Zhang
  • Ming Zhang
  • Ling Ye
Research Article

Abstract

Molecular biomarkers that can be detected in easily accessible body fluids have been proposed as non-invasive, cost-effective, and useful tools for cancer diagnosis. Recently, extensive research has explored the involvement of the aberrant expression of microRNA-21 (miRNA-21, miR-21) in lung cancer. Inconsistent results, however, have prevented its widespread use in diagnosis. In light of this situation, our meta-analysis aimed to systematically determine whether aberrant miR-21 expression can distinguish patients with lung cancer from cancer-free controls with a high level of diagnostic accuracy. A comprehensive literature search for relevant studies published before December 23, 2013 was conducted in the MEDLINE, EMBASE, the Cochrane Library, and three Chinese databases. The pooled sensitivity, specificity and other parameters were used to assess the overall performance of miR-21-based assays. Statistical analysis was conducted using the STATA 11.0 software. Eleven research articles involving 676 patients with lung cancer and 529 healthy controls were considered eligible for inclusion in the present meta-analysis. The following summary parameters were calculated from all the included studies: sensitivity of 0.66 (95 % confidence interval [CI]: 0.57–0.74), specificity of 0.82 (95 % CI: 0.74–0.88), positive likelihood ratio (PLR) of 3.70 (95 % CI: 2.50–5.60), negative likelihood ratio (NLR) of 0.42 (95 % CI: 0.32–0.54); diagnostic odds ratio (DOR) of 9.00 (95 % CI: 5.00–16.00), and area under the curve (AUC) of 0.81 (95 % CI: 0.77–0.84). In addition, we added two pre-specified covariates (ethnicity and specimen types) to the bivariate model to assess their impact on the diagnostic value of miR-21 for lung cancer. Similar results were also observed in subgroup analyses, indicating a relatively low level of accuracy. The current meta-analysis indicates that a single miR-21 may not be sufficient to identify lung cancer and that more miRNAs should be used to detect lung carcinoma.

Keywords

MicroRNA-21 Lung cancer Diagnosis Meta-analysis 

Notes

Acknowledgments

The science and technology projects from the Science and Technology Committee of Yuzhong District in Chongqing.

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.CrossRefPubMedGoogle Scholar
  2. 2.
    Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258:243–53. doi: 10.1148/radiol.10091808.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang Q, Wu X, Wu T, Li GM, Shi Y. Clinical significance of RKIP mRNA expression in non-small cell lung cancer. Tumour Biol. 2014. doi: 10.1007/s13277-013-1575-4.Google Scholar
  4. 4.
    Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med. 2007;18:175–84. doi: 10.1016/j.ejim.2006.12.001.CrossRefPubMedGoogle Scholar
  5. 5.
    O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011;12:795–805. doi: 10.1016/S1470-2045(11)70189-9.CrossRefPubMedGoogle Scholar
  6. 6.
    Zang W, Wang Y, Du Y, Xuan X, Wang T, Li M, et al. Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol. 2013. doi: 10.1007/s13277-013-1432-5.Google Scholar
  7. 7.
    Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65:6029–33. doi: 10.1158/0008-5472.CAN-05-0137.CrossRefPubMedGoogle Scholar
  8. 8.
    Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–8. doi: 10.1126/science.1064921.CrossRefPubMedGoogle Scholar
  9. 9.
    Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2010;127:2870–8. doi: 10.1002/ijc.25289.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Besse A, Sana J, Fadrus P, Slaby O. MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. Tumour Biol. 2013;34:1969–78. doi: 10.1007/s13277-013-0772-5.CrossRefPubMedGoogle Scholar
  11. 11.
    Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol. 2013;34:2093–8. doi: 10.1007/s13277-013-0940-7.CrossRefPubMedGoogle Scholar
  12. 12.
    Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766–70. doi: 10.1038/ng1590.CrossRefPubMedGoogle Scholar
  13. 13.
    Esquela-Kerscher A, Slack FJ. Oncomirs — microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69. doi: 10.1038/nrc1840.CrossRefPubMedGoogle Scholar
  14. 14.
    Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61. doi: 10.1073/pnas.0510565103.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Capodanno A, Boldrini L, Proietti A, Ali G, Pelliccioni S, Niccoli C, et al. Let-7 g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol. 2013;43:765–74. doi: 10.3892/ijo.2013.2003.PubMedGoogle Scholar
  16. 16.
    Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34:2175–81. doi: 10.1007/s13277-013-0753-8.CrossRefPubMedGoogle Scholar
  17. 17.
    Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, Araiza-Chavez J, Trevino V, Rodriguez-Padilla C, et al. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol. 2013;9:53–9. doi: 10.1111/j.1743-7563.2012.01548.x.CrossRefPubMedGoogle Scholar
  18. 18.
    Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67:170–6. doi: 10.1016/j.lungcan.2009.04.004.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol. 2012;29:3190–7. doi: 10.1007/s12032-012-0303-z.CrossRefPubMedGoogle Scholar
  20. 20.
    Abd-El-Fattah AA, Sadik NA, Shaker OG, Aboulftouh ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013;67:875–84. doi: 10.1007/s12013-013-9575-y.CrossRefPubMedGoogle Scholar
  21. 21.
    Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, et al. Analysis of microRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014;9:33–40. doi: 10.1097/jto.0000000000000025.CrossRefPubMedGoogle Scholar
  22. 22.
    Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36. doi: 10.7326/0003-4819-155-8-201110180-00009.CrossRefPubMedGoogle Scholar
  23. 23.
    Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Hamza TH, Arends LR, van Houwelingen HC, Stijnen T. Multivariate random effects meta-analysis of diagnostic tests with multiple thresholds. BMC Med Res Methodol. 2009;9:73. doi: 10.1186/1471-2288-9-73.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. doi: 10.1136/bmj.327.7414.557.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–93. doi: 10.1016/j.jclinepi.2005.01.016.CrossRefPubMedGoogle Scholar
  27. 27.
    Li Y, Li W, Ouyang Q, Hu S, Tang J. Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncol Lett. 2011;2:991–4. doi: 10.3892/ol.2011.351.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91:579–87. doi: 10.1038/labinvest.2010.194.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Wei J, Liu LK, Gao W, Zhu CJ, Liu YQ, Cheng T, et al. Reduction of plasma MicroRNA-21 is associated with chemotherapeutic response in patients with non-small cell lung cancer. Chin J Cancer Res. 2011;23:123–8. doi: 10.1007/s11670-011-0123-2.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138:1659–66. doi: 10.1007/s00432-012-1244-9.CrossRefPubMedGoogle Scholar
  31. 31.
    Mozzoni P, Banda I, Goldoni M, Corradi M, Tiseo M, Acampa O, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 2013;18:679–86. doi: 10.3109/1354750x.2013.845610.CrossRefPubMedGoogle Scholar
  32. 32.
    Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013;22:540–8. doi: 10.1097/CEJ.0b013e32835f3be9.CrossRefPubMedGoogle Scholar
  33. 33.
    Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011;30:407–14.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011;8:706–13. doi: 10.4161/rna.8.5.16154.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Gao W, Xu J, Liu L, Shen H, Zeng H, Shu Y. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother. 2012;66:21–8. doi: 10.1016/j.biopha.2011.09.004.CrossRefPubMedGoogle Scholar
  36. 36.
    Huang Y, Hu Q, Deng Z, Hang Y, Wang J, Wang K. MicroRNAs in body fluids as biomarkers for non-small cell lung cancer: a systematic review. Technol Cancer Res Treat. 2013. doi: 10.7785/tcrt.2012.500377.Google Scholar
  37. 37.
    Vannini I, Fanini F, Fabbri M. MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin Biochem. 2013;46:918–25. doi: 10.1016/j.clinbiochem.2013.01.024.CrossRefPubMedGoogle Scholar
  38. 38.
    Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen. 2003;10:47–51.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Renjie Wu
    • 1
  • Yingjiu Jiang
    • 1
  • Qingcheng Wu
    • 1
  • Qiang Li
    • 1
  • Dan Cheng
    • 1
  • Ling Xu
    • 1
  • Cheng Zhang
    • 1
  • Ming Zhang
    • 1
  • Ling Ye
    • 1
  1. 1.Department of Cardiothoracic SurgeryFirst Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations